1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one
- Product Name
- 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one
- CAS No.
- 1792180-81-4
- Chemical Name
- 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one
- Synonyms
- Ritlecitinib;PF-06651600;CS-2733;EOS-61890;Ritlecitinib (PF-06651600);PF-06651600;PF 06651600;PF06651600;Ritlecitinib free base PF-06651600;Janus kinase,Inhibitor,inhibit,PF06651600,Ritlecitinib,JAK,PF 06651600;1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2;1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one
- CBNumber
- CB23142473
- Molecular Formula
- C15H19N5O
- Formula Weight
- 285.34
- MOL File
- 1792180-81-4.mol
1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one Property
- Density
- 1.272±0.06 g/cm3(Predicted)
- storage temp.
- room temp
- solubility
- DMSO:100.0(Max Conc. mg/mL);350.4(Max Conc. mM)
H2O:5.0(Max Conc. mg/mL);17.5(Max Conc. mM) - form
- powder
- pka
- 13.03±0.50(Predicted)
- color
- white to beige
- InChI
- InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1
- InChIKey
- CBRJPFGIXUFMTM-WDEREUQCSA-N
- SMILES
- C(N1C[C@H](NC2N=CN=C3NC=CC3=2)CC[C@@H]1C)(=O)C=C
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- PZ0316
- Product name
- PF-06651600
- Purity
- ≥98% (HPLC)
- Packaging
- 5MG
- Price
- $105
- Updated
- 2023/06/20
- Product number
- PZ0316
- Product name
- PF-06651600
- Purity
- ≥98% (HPLC)
- Packaging
- 25MG
- Price
- $339
- Updated
- 2023/06/20
- Product number
- 462323
- Product name
- PF-06651600
- Packaging
- 1mg
- Price
- $319
- Updated
- 2021/12/16
- Product number
- 474159
- Product name
- PF06651600
- Packaging
- 100mg
- Price
- $2315
- Updated
- 2021/12/16
- Product number
- CS-0020243
- Product name
- Ritlecitinib
- Purity
- 99.98%
- Packaging
- 5mg
- Price
- $80
- Updated
- 2021/12/16
1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one Chemical Properties,Usage,Production
Description
Ritlecitinib, a dual JAK3/TEC inhibitor, was granted FDA breakthrough status for treating alopecia areata (autoimmune-induced hair loss) in September 2018. Promising phase 3 trial results in alopecia areata were reported by Pfizer in August 2021, placing it in competition with Lilly/Incyte’s Olumiant. It is also used in clinical studies to treat vitiligo, rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. Ritlecitinib achieved high JAK3 selectivity via covalent interaction with a unique cysteine residue (Cys909) in the catalytic domain.
Characteristics
Primary targets: JAK3/TEC
Class: non-receptor tyrosine kinase
Treatment: alopecia areata (phase III)
Protein binding = 14%
Biochem/physiol Actions
PF-06651600 is a potent and selective JAK3 inhibitor.
Pharmacokinetics
Ritlecitinib exhibited low clearance in rats and dogs, contributing to its good oral bioavailability (85% in rats and 109% in dogs). Its lower oral bioavailability in monkeys (56%) primarily resulted from its fast clearance. The pharmacokinetic properties are directly linked to its stability in hepatocytes and whole blood, demonstrating the power of in vitro assays to predict in vivo pharmacokinetic parameters. The good oral bioavailability obtained from rats and dogs was a combination of high passive permeability, high aqueous solubility (>2 mg/mL), and low hepatic clearance. Ritlecitinib underwent CYP3A4-mediated oxidation of the acrylamide and piperidine ring and glutathione conjugated with the acrylamide. Allometric scaling predicted an oral bioavailability of 90% and a half-life of 2 h in humans, which need to be verified in clinical trials.
1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one Preparation Products And Raw materials
Raw materials
Preparation Products
1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one Suppliers
- Tel
- +1-781-999-5354 +1-00000000000
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32165
- Advantage
- 58
- Tel
- +1-708-310-1919 +1-13798911105
- Fax
- 708-557-7486
- sales@invivochem.cn
- Country
- United States
- ProdList
- 6391
- Advantage
- 58
- Tel
- +1 (732)236-3202
- sales@cckinase.com
- Country
- United States
- ProdList
- 2738
- Advantage
- 58
- Tel
- +1-631-485-4226
- Fax
- 1-631-614-7828
- inquiry@bocsci.com
- Country
- United States
- ProdList
- 19553
- Advantage
- 58
- Tel
- +1-+1(833)-552-7181
- sales@aladdinsci.com
- Country
- United States
- ProdList
- 57505
- Advantage
- 58
- Tel
- support@targetmol.com
- Country
- United States
- ProdList
- 38632
- Advantage
- 58
- Tel
- --
- Fax
- --
- sales@advtechind.com
- Country
- United States
- ProdList
- 6075
- Advantage
- 58
- Tel
- --
- Fax
- --
- chemicals@usbio.net
- Country
- United States
- ProdList
- 6214
- Advantage
- 80
View Lastest Price from 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one manufacturers
- Product
- Ritlecitinib 1792180-81-4
- Price
- US $50.00/g
- Min. Order
- 10g
- Purity
- 99%
- Supply Ability
- 10KG/M
- Release date
- 2023-08-17
- Product
- Ritlecitinib 1792180-81-4
- Price
- US $0.00-0.00/kg
- Min. Order
- 0.10000000149011612kg
- Purity
- 99%
- Supply Ability
- 5000kg
- Release date
- 2024-08-07
- Product
- Ritlecitinib 1792180-81-4
- Price
- US $0.00/g
- Min. Order
- 1g
- Purity
- 99% min
- Supply Ability
- 20 kg
- Release date
- 2024-08-20